Report: Current Stock Reports

Conclusion of an amendment to global License Agreement with Menarini Group
September 14, 2023

Conclusion of two agreements in the area of operational execution of RVU120 Phase II clinical trials in hematology
August 4, 2023

Conclusion of a financing agreement with the Medical Research Agency
July 31, 2023

Conclusion of the agreement in the area of securing venetoclax supply chain for RVU120 Phase II clinical trial in combination therapy in hematology
July 31, 2023

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
July 21, 2023

Conclusion of two agreements in the area of data management and biostatistics for RVU120 Phase II clinical trials in hematology
July 14, 2023

Conclusion of two agreements with Zakłady Farmaceutyczne Polpharma S.A. in the area of RVU120 active substance (API) production for Phase II clinical trials
July 6, 2023

Registration of an amendment to the Articles of Association of the Company concerning conditional increase in the share capital of the Company
June 19, 2023

Appointment of new Members of the Supervisory Board of Ryvu Therapeutics S.A.
June 14, 2023

Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 14th, 2023
June 14, 2023